THE SANFORD GUIDE TO ANTIMICROBIAL THERAPY 2019 (LIBRARY EDITION)

THE SANFORD GUIDE TO ANTIMICROBIAL THERAPY 2019 (LIBRARY EDITION)

Editorial:
ANTIMICROBIAL THERAPY
Año de edición:
Materia
Medicina Interna
ISBN:
978-1-944272-11-1
Páginas:
200
N. de edición:
49
Idioma:
Inglés
Disponibilidad:
Disponible en 2 semanas

Descuento:

-5%

Antes:

66,00 €

Despues:

62,70 €

The 49th edition of the leading clinical reference on treatment of infectious diseases and anti-infective drug information. Helpful in day-to-day practice and as a component of your organization's antimicrobial stewardship program, the Sanford Guide provides valuable guidance in the age of antibiotic resistance. Popular with physicians, pharmacists, physician assistants, nurse practitioners, and other clinicians, the Sanford Guide to Antimicrobial Therapy provides information that is convenient, concise, and reliable.
Available in print in pocket size, spiral bound and large library editions.
Coverage includes:
Clinical syndromes
• pathogens
• bacterial
• fungal
• mycobacterial
• parasitic
• viral
Anti-infective agents
• dosing
pediatric adjustments
renal adjustments
• adverse affects
• activity
• pharmacology
• interactions
Preventative therapy
What's new in 2019:
• Table 1: osteomyelitis, mastitis, brain abscess, encephalitis, meningitis, otitis media, keratitis, gastroenteritis, urethritis, syphilis, pyelonephritis, vaginosis, endocarditis, prosthetic joint, UTIs, pneumonia (esp. GNB), pancreatitis, peritonitis, bites, burns, cellulitis, Lyme, febrile syndromes, sepsis, shock, botulism, IV lines/catheters, vascular
• Table 2: resistant bacteria, including GNB
• Table 3: duration of therapy
• Table 4: organism coverage expanded, drugs added (new and old)
• Table 5B: updated treatment options for GNB
• Table 6: updated recommendations for management of MRSA
• Table 8: pregnancy risk for new drugs
• Table 9: PK & interactions data for new drugs added
• Table 10: dosing updated and recent drugs added, e.g., plazomicin, eravacycline, omadacycline, temocillin, secnidazole
• Table 11: cryptococcosis
• Table 12: latent TB, MAC, M. abscessus
• Table 13: malaria, tafenoquine
• Table 14A: hemorrhagic fevers, influenza
• Table 14B: new HCV, CMV drugs
• Table 14C: new ARV drugs & combinations, updated recommended ART regimens
• Table 14F: updated HCV treatment regimens and recommendations
• Table 15: post-exposure prophylaxis
• Table 16: added peds dosing for additional antibacterials, ARVs, antivirals
• Table 17: renal adjustments for new drugs added
• Table 17C: updated obesity dose adjustments
• Table 22: DDIs completely reworked to focus on effects and suggested management

Otros libros del autor